Intismeran clinical trials

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

This study is for people with early-stage lung cancer (NSCLC) that's been removed by surgery but has a high chance of coming back. Researchers want to see if new medicines, Intismeran and Pembrolizumab, can help stop the cancer from returning, compared to a dummy drug.